TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19205545

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional treatment plus placebo
Number of subjects: 22
Study: 16910456

Group type: EXPERIMENTAL
Intervention: Classical cotton swab
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Urethral cotton swab
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Balloon shape cotton swab
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cyto‐brush
Number of subjects: 100
Study: 11772176

Group type: EXPERIMENTAL
Intervention: Modified Rakosi Functional Analysis
Number of subjects: 30
Study: 10352617

Group type: EXPERIMENTAL
Intervention: NC100150 injection with respiratory gating
Number of subjects: 9
Study: 9082765

Group type: EXPERIMENTAL
Intervention: Intranasal immunization with P6 (twice, with 2 weeks in between)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intranasal administration of rIL-2 and rIL-5
Number of subjects: 24
Study: 1937985

Group type: EXPERIMENTAL
Intervention: gallopamil (50 mg thrice daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: diltiazem (60 mg thrice daily)
Number of subjects: 12
Study: 6128086

Group type: EXPERIMENTAL
Intervention: Pirbuterol (PB) 20 mg three times daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pirbuterol (PB) 20 mg and 30 mg doses
Number of subjects: 12
Study: 30950094

Group type: EXPERIMENTAL
Intervention: e-Cigarettes
Number of subjects: 0
Study: 28844499

Group type: EXPERIMENTAL
Intervention: Rindopepimut (500 μg admixed with 150 μg GM‐CSF) plus standard oral temozolomide (150–200 mg/m2 for 5 of 28 days) for 6–12 cycles or longer.
Number of subjects: 745

Group type: COMPARATOR
Intervention: Control (100 μg keyhole limpet haemocyanin) plus standard oral temozolomide (150–200 mg/m2 for 5 of 28 days) for 6–12 cycles or longer.
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: Rindopepimut group
Number of subjects: 745

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 745
Study: 24615546

Group type: EXPERIMENTAL
Intervention: CMCA (community environmental change intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CONNECT (population-wide intervention based on SBIRT)
Number of subjects: 0
Study: 23957500

Group type: EXPERIMENTAL
Intervention: Novel image analysis tool for TEM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional diagnostic approaches without the novel tool
Number of subjects: 0
Study: 21406671

Group type: EXPERIMENTAL
Intervention: SUSTAIN intervention (chronic care model-based program including group clinics, self-management support, report cards, decision support through care guides and protocols, and coordination of ongoing care)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: SUSTAIN intervention
Number of subjects: 268
Study: 19269731

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine digluconate (CAVITY CLEANSER) applied for 60s on acid etched dentine
Number of subjects: 3

Group type: COMPARATOR
Intervention: No chlorhexidine treatment (Control)
Number of subjects: 3
Study: 17381964

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) 3.9 g/d
Number of subjects: 62

Group type: COMPARATOR
Intervention: High-oleic acid sunflower oil
Number of subjects: 62
Study: 15200656

Group type: EXPERIMENTAL
Intervention: Rofecoxib 1 mg x kg(‐1) (max 25 mg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 11396396

Group type: EXPERIMENTAL
Intervention: PRK
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control (fellow unoperated eyes)
Number of subjects: 97
Study: 9413764

Group type: EXPERIMENTAL
Intervention: Zinc content in benign prostatic hyperplasia (BPH)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Zinc content in cancer
Number of subjects: 109

Group type: COMPARATOR
Intervention: Zinc content in normal prostate
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Zinc assessment in transrectal puncture biopsy
Number of subjects: 109
Study: 8387191

Group type: EXPERIMENTAL
Intervention: Budesonide (2 x 400 micrograms/d by spacer)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nedocromil (4 x 4 mg/d)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nedocromil
Number of subjects: 15
Study: 3440107

Group type: EXPERIMENTAL
Intervention: Rectally administered carbamazepine mixture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Orally administered carbamazepine mixture
Number of subjects: 0
Study: 31888762

Group type: EXPERIMENTAL
Intervention: 1000 mg omega-3 fatty acid twice a day + vitamin D placebo every two weeks
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid placebo twice a day + 50,000 IU vitamin D every two weeks
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: 1000 mg omega-3 fatty acid twice a day + 50,000 IU vitamin D every two weeks
Number of subjects: 168

Group type: COMPARATOR
Intervention: Omega-3 fatty acid placebo twice a day + vitamin D placebo every two weeks
Number of subjects: 168
Study: 28899842

Group type: EXPERIMENTAL
Intervention: Prompting intervention
Number of subjects: 0
Study: 27156748

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 151

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 151

Group type: COMPARATOR
Intervention: No acupuncture
Number of subjects: 151
Study: 24862674

Group type: EXPERIMENTAL
Intervention: Harmonic(®) FOCUS
Number of subjects: 82

Group type: COMPARATOR
Intervention: Traditional suture ligation (knot and tie)
Number of subjects: 82
Study: 22421498

Group type: EXPERIMENTAL
Intervention: Web-based tutorial
Number of subjects: 347

Group type: COMPARATOR
Intervention: No tutorial
Number of subjects: 347
Study: 20072045

Group type: EXPERIMENTAL
Intervention: HMB + KIC (3 g.d HMB and 0.3 g.d KIC)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (3 g.d corn flour)
Number of subjects: 14
Study: 17492341

Group type: EXPERIMENTAL
Intervention: Partly absorbable polypropylene-polyglactin mesh (Vypro II(R) 50 g/m(2), 79 hernias)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Lightweight polypropylene mesh (Premilene Mesh LP(R) 55 g/m(2), 75 hernias)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Conventional densely woven polypropylene mesh (Premilene(R) 82 g/m(2), 78 hernias)
Number of subjects: 228

Group type: COMPARATOR
Intervention: All meshes (Vypro, Premilene LP, Premilene)
Number of subjects: 228
Study: 15630054

Group type: EXPERIMENTAL
Intervention: Full 6‐year intervention (grades 1 through 6)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Late 2‐year intervention (grades 5 and 6 only)
Number of subjects: 605

Group type: COMPARATOR
Intervention: No‐treatment control condition
Number of subjects: 605
Study: 11852171

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10194170

Group type: EXPERIMENTAL
Intervention: Sodium salicylate (SSA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LASA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 7780288

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 37

Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 37
Study: 2194652

Group type: EXPERIMENTAL
Intervention: Simultaneous infusion of methotrexate and teniposide
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sequential infusion of methotrexate followed by teniposide
Number of subjects: 19
Study: 344012

Group type: COMPARATOR
Intervention: Sch 1000 (200 microgram)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sch 1000 (400 microgram)
Number of subjects: 24
Study: 31333114

Group type: EXPERIMENTAL
Intervention: Oral morphine
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: All opioids
Number of subjects: 62
Study: 26053503

Group type: EXPERIMENTAL
Intervention: Hydrophobic chlorhexidine‐based gingiva‐adhering gel (applied once every second day for 14 days)
Number of subjects: 34

Group type: COMPARATOR
Intervention: 1% chlorhexidine water‐soluble gel (applied twice daily)
Number of subjects: 34
Study: 25373742

Group type: EXPERIMENTAL
Intervention: SEBT grid training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Stationary cycling (Control)
Number of subjects: 60
Study: 23529567

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 2.5 mg/day
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg/day
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 597

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 597
Study: 21318011

Group type: EXPERIMENTAL
Intervention: Blocked randomization with randomly selected block sizes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple random allocation scheme
Number of subjects: 0
Study: 19556470

Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise (NE) training program
Number of subjects: 74

Group type: COMPARATOR
Intervention: Strength exercise (SE) training program
Number of subjects: 74
Study: 16030082

Group type: EXPERIMENTAL
Intervention: Lumbar epidural corticosteroid injections (ESI) of triamcinolone acetonide, administered three times at intervals of 3 weeks.
Number of subjects: 228

Group type: COMPARATOR
Intervention: Interligamentous saline injections (placebo control), administered three times at intervals of 3 weeks.
Number of subjects: 228
Study: 12042368

Group type: EXPERIMENTAL
Intervention: N(G)‐monomethyl‐L‐arginine (L‐NMMA) (3 mg kg(‐1))
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Phenylephrine (100 microg)
Number of subjects: 9
Study: 10064291

Group type: EXPERIMENTAL
Intervention: Telephone intervention discussing maternal distress and infant difficulty
Number of subjects: 78
Study: 7674244

Group type: EXPERIMENTAL
Intervention: TEAMCARE (team managed outpatient care program)
Number of subjects: 118

Group type: COMPARATOR
Intervention: TRADCARE (traditional nonteam managed rheumatologic care)
Number of subjects: 118

Group type: COMPARATOR
Intervention: TEAMCARE and TRADCARE
Number of subjects: 118
Study: 2275890

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 0
Study: 7029318

Group type: EXPERIMENTAL
Intervention: Captopril therapy
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Propranolol therapy
Number of subjects: 16
Study: 31564317

Group type: EXPERIMENTAL
Intervention: Latanoprost administration
Number of subjects: 156

Group type: COMPARATOR
Intervention: Discontinuation of latanoprost
Number of subjects: 156
Study: 28417704

Group type: EXPERIMENTAL
Intervention: Silver nitrate cauterization of the left middle turbinate (MT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (noncauterized right middle turbinate)
Number of subjects: 38
Study: 26444095

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 23808222

Group type: EXPERIMENTAL
Intervention: Preoperative photodynamic therapy (PhT) using chlorine E6 and light of wavelength 662 nm
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group without photodynamic therapy (PhT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Preoperative photodynamic therapy (PhT)
Number of subjects: 42
Study: 21920260

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer drug-eluting stents (n = 1,299)
Number of subjects: 2603

Group type: COMPARATOR
Intervention: Permanent polymer drug-eluting stents (n = 1,304)
Number of subjects: 2603

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES) (n = 652)
Number of subjects: 2603

Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES) (n = 652)
Number of subjects: 2603
Study: 19810365

Group type: EXPERIMENTAL
Intervention: Retinonic acid
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cleanser
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All four medications
Number of subjects: 100
Study: 16500018

Group type: EXPERIMENTAL
Intervention: 30% oxygen (group A)
Number of subjects: 28

Group type: COMPARATOR
Intervention: 100% oxygen (group B)
Number of subjects: 28
Study: 15572523

Group type: EXPERIMENTAL
Intervention: Multiple breath-hold averaged (1)H-MRS at high field (3T) in renal cell carcinoma tumors
Number of subjects: 24

Group type: COMPARATOR
Intervention: Multiple breath-hold averaged (1)H-MRS at high field (3T) in healthy kidneys
Number of subjects: 24
Study: 12177646

Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 317

Group type: COMPARATOR
Intervention: Amiodarone treatment
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: ICD therapy with > or =5 shocks
Number of subjects: 317
Study: 9952095

Group type: EXPERIMENTAL
Intervention: Caffeine sodium benzoate (500 mg) in 1,000 mL normal saline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (placebo) in 1,000 mL
Number of subjects: 60
Study: 8525855

Group type: EXPERIMENTAL
Intervention: Diagnostic assessment and child video recording observation
Number of subjects: 10
Study: 2259226

Group type: EXPERIMENTAL
Intervention: DA (daunorubicin 45 mg/m2/day x 3)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: MA (m-AMSA 200 mg/m2/day x 3 days)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: MA (m-AMSA)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: DA (daunorubicin)
Number of subjects: 299

Group type: COMPARATOR
Intervention: No maintenance
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: DA every 13 weeks x 4 cycles
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Continuous relapse-free survivors
Number of subjects: 299
Study: 7402449

Group type: EXPERIMENTAL
Intervention: 1.2 mg naloxone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study: 31282447

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) intervention
Number of subjects: 71

Group type: COMPARATOR
Intervention: Sham chamber sessions (control)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Healthy controls (no intervention)
Number of subjects: 71
Study: 28192477

Group type: EXPERIMENTAL
Intervention: Early pharmacist-led medication review
Number of subjects: 10407

Group type: EXPERIMENTAL
Intervention: Early pharmacist-led medication review (for patients under 80 years)
Number of subjects: 10407

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10407
Study: 26486192

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: All groups (Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg and 300 mg
Number of subjects: 351
Study: 24256460

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate dressing (BMV)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Calcipotriol-betamethasone dipropionate ointment (CBD)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Both BMV and CBD
Number of subjects: 324
Study: 23021506

Group type: EXPERIMENTAL
Intervention: PHiD-CV co-administered with routine childhood vaccines
Number of subjects: 230
Study: 19782914

Group type: EXPERIMENTAL
Intervention: Selective inhibitors of factor Xa and thrombin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional anticoagulants (heparins and vitamin K antagonists)
Number of subjects: 0
Study: 17313293

Group type: EXPERIMENTAL
Intervention: 6‐mg x kg(‐1) dose of caffeine
Number of subjects: 20

Group type: COMPARATOR
Intervention: 3‐mg x kg(‐1) dose of caffeine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15360029

Group type: EXPERIMENTAL
Intervention: Complete pressure relief (5 mm Hg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Partial pressure relief (20 mm Hg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Full pressure relief (0 mm Hg)
Number of subjects: 28
Study: 11677377

Group type: EXPERIMENTAL
Intervention: Valsartan + Hydrochlorothiazide (12.5 mg/day)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Valsartan + Benazepril (10 mg/day)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Valsartan (80 mg/day) alone
Number of subjects: 327
Study: 9674442

Group type: EXPERIMENTAL
Intervention: Anabolic steroids (250 mg testosterone i.m. at baseline and 12 mg oral stanozolol daily for 27 weeks)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Anabolic steroids
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 23
Study: 8023059

Group type: EXPERIMENTAL
Intervention: DFO (Deferoxamine) at a low dose of 10 mg/kg body weight per week
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cuprophan membrane CF1511
Number of subjects: 10

Group type: COMPARATOR
Intervention: Polysulfone membrane F60
Number of subjects: 10

Group type: COMPARATOR
Intervention: Calcium carbonate and calcium acetate phosphate binders
Number of subjects: 10

Group type: COMPARATOR
Intervention: Regular controls of plasma aluminium levels
Number of subjects: 10
Study: 2587017

Group type: EXPERIMENTAL
Intervention: Solcoseryl eye drops
Number of subjects: 94

Group type: COMPARATOR
Intervention: Vitasic eye drops
Number of subjects: 94
Study: 4938640

Group type: EXPERIMENTAL
Intervention: Marihuana
Number of subjects: 0
Study: 30102051

Group type: EXPERIMENTAL
Intervention: ADAPT (After Deployment Adaptive Parenting Tools), a 14-week group-based intervention
Number of subjects: 336

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 336
Study: 27287201

Group type: EXPERIMENTAL
Intervention: SVelter algorithm for resolving complex chromosomal rearrangements
Number of subjects: 0
Study: 24628437

Group type: EXPERIMENTAL
Intervention: Intra-pocket lidocaine and prilocaine gel (2.5% each)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Injected articaine (1:100,000 adrenaline)
Number of subjects: 38
Study: 22669588

Group type: EXPERIMENTAL
Intervention: UC-HDF
Number of subjects: 30

Group type: COMPARATOR
Intervention: sOL-HDF
Number of subjects: 30
Study: 20488929

Group type: EXPERIMENTAL
Intervention: Subarachnoid morphine (group SAM; n = 28)
Number of subjects: 57
Study: 18663493

Group type: EXPERIMENTAL
Intervention: Postoperative maxillo-mandibular fixation (MMF) for 13 patients for 1 week after SSRO
Number of subjects: 27

Group type: COMPARATOR
Intervention: No postoperative maxillo-mandibular fixation for 14 patients, occlusal guidance with elastics starting from the third postoperative day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups (MMF and no MMF)
Number of subjects: 27
Study: 16146573

Group type: EXPERIMENTAL
Intervention: Implant supported dentures
Number of subjects: 117

Group type: COMPARATOR
Intervention: High quality conventional dentures
Number of subjects: 117
Study: 12460093

Group type: EXPERIMENTAL
Intervention: Information plus interview group
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: Information alone group
Number of subjects: 894

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 894
Study: 10063488

Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 g/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ethanol (0.2 g/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ethanol administration
Number of subjects: 20
Study: 7726267

Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg single oral dose
Number of subjects: 429

Group type: COMPARATOR
Intervention: Clotrimazole 100 mg vaginal treatment for 7 days
Number of subjects: 429
Study: 2185294

Group type: EXPERIMENTAL
Intervention: Thymopentin (Timunox, n = 48)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (n = 52)
Number of subjects: 100
Study: 7021058

Group type: EXPERIMENTAL
Intervention: Calcium carbonate dentifrice
Number of subjects: 27

Group type: COMPARATOR
Intervention: Water
Number of subjects: 27
Study: 31035665

Group type: EXPERIMENTAL
Intervention: Low Amplitude Seizure Therapy (LAP‐ST) at 500mA
Number of subjects: 7

Group type: COMPARATOR
Intervention: Standard Right Unilateral Electroconvulsive Therapy (RUL ECT) at 900 mA
Number of subjects: 7
Study: 29111172

Group type: EXPERIMENTAL
Intervention: Nutritional counseling plus oral nutritional supplements (ONS)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Nutritional counseling without oral nutritional supplements (ONS)
Number of subjects: 159
Study: 27389341

Group type: EXPERIMENTAL
Intervention: Mother-Infant Bonding Questionnaire (MIBQ)
Number of subjects: 751
Study: 25268205

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone (cohort 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with a monoclonal antibody (cohort 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical resection of metastasis (cohort 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical resection of metastasis (cohort 2)
Number of subjects: 0
Study: 22473458

Group type: EXPERIMENTAL
Intervention: Combination of valsartan and captopril
Number of subjects: 116

Group type: COMPARATOR
Intervention: Captopril alone (ACEI group)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Additional ARB therapy
Number of subjects: 116
Study: 20413119

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17609871

Group type: EXPERIMENTAL
Intervention: Radiotherapy with razoxane (group B)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Radiotherapy alone (group A)
Number of subjects: 36
Study: 16223969

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy plus medical management for medication taper (CBT-MM)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Medical management alone (MM)
Number of subjects: 42
Study: 12407044

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer (group 1)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Clinical touch embryo transfer (group 2)
Number of subjects: 184